<PAPER><mode2 name='PMC3350354' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='iso-abbrev'>Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type='publisher-id'>DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type='epub'>1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3350354</article-id><article-id pub-id-type='pmid'>22619661</article-id><article-id pub-id-type='doi'>10.1159/000336710</article-id><article-id pub-id-type='publisher-id'>dee-0002-0057</article-id><article-categories><subj-group subj-group-type='heading'><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>CNS Medications as Predictors of Precipitous Cognitive Decline in the Cognitively Disabled Aged: A Longitudinal Population-Based Study</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Puustinen</surname><given-names>Juha</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref><xref rid='aff6' ref-type='aff'><sup>f</sup></xref><xref rid='cor1' ref-type='corresp'>*</xref></contrib><contrib contrib-type='author'><name><surname>Nurminen</surname><given-names>Janne</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff3' ref-type='aff'><sup>c</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref><xref rid='aff6' ref-type='aff'><sup>f</sup></xref></contrib><contrib contrib-type='author'><name><surname>Vahlberg</surname><given-names>Tero</given-names></name><xref rid='aff2' ref-type='aff'><sup>b</sup></xref></contrib><contrib contrib-type='author'><name><surname>Lyles</surname><given-names>Alan</given-names></name><xref rid='aff7' ref-type='aff'><sup>g</sup></xref><xref rid='aff8' ref-type='aff'><sup>h</sup></xref></contrib><contrib contrib-type='author'><name><surname>Isoaho</surname><given-names>Raimo</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref></contrib><contrib contrib-type='author'><name><surname>Räihä</surname><given-names>Ismo</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref></contrib><contrib contrib-type='author'><name><surname>Kivelä</surname><given-names>Sirkka-Liisa</given-names></name><xref rid='aff1' ref-type='aff'><sup>a</sup></xref><xref rid='aff4' ref-type='aff'><sup>d</sup></xref><xref rid='aff7' ref-type='aff'><sup>g</sup></xref></contrib></contrib-group><aff id='aff1'><sup>a</sup>Department of Family Medicine, University of Turku, Turku and Pori, Pori</aff><aff id='aff2'><sup>b</sup>Department of Biostatistics, University of Turku, Turku and Pori, Pori</aff><aff id='aff3'><sup>c</sup>Department of Turku Health Centre, Turku and Pori, Pori</aff><aff id='aff4'><sup>d</sup>Department of Primary Health Care, Turku University Hospital and Satakunta Central Hospital, Hospital Districts of Southwest Finland and Satakunta, Turku and Pori, Pori</aff><aff id='aff5'><sup>e</sup>Unit of Geriatrics, Satakunta Central Hospital, Pori</aff><aff id='aff6'><sup>f</sup>Härkätie Health Centre, Lieto, University of Helsinki, Helsinki, Finland</aff><aff id='aff7'><sup>g</sup>Division of Social Pharmacy, University of Helsinki, Helsinki, Finland</aff><aff id='aff8'><sup>h</sup>College of Public Affairs, School of Health and Human Services, University of Baltimore, Baltimore, Md., USA</aff><author-notes><corresp id='cor1'>*Dr. Juha Puustinen, MD, Department of Family Medicine, University of Turku, Lemminkäisenkatu 1, FI–20014 University of Turku (Finland), Tel. +358 400 801 545, E-Mail <email>juhpuu@utu.fi</email></corresp></author-notes><pub-date pub-type='collection'><season>Jan-Dec</season><year>2012</year></pub-date><pub-date pub-type='epub'><day>16</day><month>3</month><year>2012</year></pub-date><pub-date pub-type='pmc-release'><day>16</day><month>3</month><year>2012</year></pub-date><volume>2</volume><issue>1</issue><fpage>57</fpage><lpage>68</lpage><permissions><copyright-statement>Copyright © 2012 by S. Karger AG, Basel</copyright-statement><copyright-year>2012</copyright-year><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc-nd/3.0/'>http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on <ext-link ext-link-type='uri' xlink:href='http://www.karger.com'>http://www.karger.com</ext-link> and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background/Aims</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Psychotropics and antiepileptics (AE) are medications commonly used among the aged with cognitive decline or dementia, although they may precipitate further cognitive decline.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Our aim was to analyze the relationships between the use of (i) psychotropics (i.e. benzodiazepines or related drugs, BZD, antipsychotics, AP, or antidepressants, AD), opioids (Op), anticholinergics (ACh) or AEs or the concomitant use of two of these drugs, and (ii) the risk of precipitous cognitive decline in an older (≥65 years) cognitively disabled population.</s></p></sec><sec><title>Methods</title><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A longitudinal population-based study of general aged community-dwelling patients was executed in two phases (1990–1991 and 1998–1999) in Lieto, Finland.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Fifty-two individuals cognitively disabled (MMSE score 0–23) at the 1990–1991 baseline form this study's sample.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Cognitive abilities were assessed in each phase with the Mini-Mental State Examination (MMSE) and medication utilization data were collected in both phases.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The mean follow-up time was 7.6 years.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Multivariate models were used to analyze the change in MMSE total score between medication users and non-users.</s></p></sec><sec><title>Results</title><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>BZD or any psychotropic use was associated with greater cognitive decline in elders aged ≥75 years compared to non-users (change in MMSE sum score: −8.6 ± 7.0 vs. −3.3 ± 5.6 and −5.9 ± 7.0 vs. −2.7 ± 6.4, respectively).</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> A greater decline was also associated specifically with the concomitant use of BZD and AP (–16 vs. −1.4 ± 7.8); as were BZD and any drug with CNS effects (–9.6 ± 9.9 vs. −1.3 ± 7.2) compared to non-users.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The concomitant use of BZD and AD (–10.7 ± 4.7 vs. −3.2 ± 5.6) or ACh (–15.0 ± 8.5 vs. −3.3 ± 5.6) or any drug with CNS effects (–13.3 ± 6.5 vs. −3.3 ± 5.6) was associated with cognitive decline in patients ≥75 years compared to non-users of any drug with CNS effects.</s></p></sec><sec><title>Conclusion</title><p><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>The use of a BZD or any psychotropic medication may be an independent risk factor for cognitive decline in the cognitively disabled aged, and patients co-prescribed psychotropic medications had greater cognitive decline.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Studies with larger sample sizes and studies on possible pathophysiologic mechanisms are needed.</s></p></sec></abstract><kwd-group><title>Key Words</title><kwd>Aged</kwd><kwd>CNS agents</kwd><kwd>Benzodiazepines</kwd><kwd>Parasympatholytics</kwd><kwd>Cholinergic antagonists</kwd><kwd>Memory disorders</kwd><kwd>Delirium disorders</kwd><kwd>Dementia disorders</kwd><kwd>Amnestic disorders</kwd><kwd>Cognitive disorders</kwd></kwd-group><counts><table-count count='5'></table-count><ref-count count='45'></ref-count><page-count count='12'></page-count></counts></article-meta></front><body><sec id='sec1_1'><title>Introduction</title><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Psychotropics [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>,<xref rid='B4' ref-type='bibr'>4</xref>] and antiepileptic medications [<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B7' ref-type='bibr'>7</xref>] are commonly used to treat the behavioral and psychological symptoms of dementia [<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A concern, however, has arisen as to whether these medications may lead to a precipitous cognitive deterioration among patients with pre-existing cognitive decline or dementing diseases.</s></p><p><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Conventional antipsychotics (AP) can cause anticholinergic and extrapyramidal adverse effects in the aged [<xref rid='B9' ref-type='bibr'>9</xref>].</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A randomized, placebo-controlled trial failed to show a positive benefit/risk ratio for the use of APs among home-dwelling elders with Alzheimer's disease [<xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Some longitudinal epidemiologic studies [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B12' ref-type='bibr'>12</xref>] and randomized controlled trials [<xref rid='B13' ref-type='bibr'>13</xref>,<xref rid='B14' ref-type='bibr'>14</xref>] have shown that AP use is related to a precipitous cognitive decline among patients with dementing diseases.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This relationship has not been reported in other longitudinal epidemiologic studies [<xref rid='B15' ref-type='bibr'>15</xref>,<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>,<xref rid='B18' ref-type='bibr'>18</xref>] or short-term treatment studies [<xref rid='B10' ref-type='bibr'>10</xref>,<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B20' ref-type='bibr'>20</xref>,<xref rid='B21' ref-type='bibr'>21</xref>].</s></p><p><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>There is some evidence of an association between the use of medications other than APs which have CNS effects and cognitive decline.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Benzodiazepines or related drugs (BZD) may worsen cognition in patients with Alzheimer's disease, especially when combined with APs [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Antidepressants (AD) with anticholinergic properties (especially tricyclic ADs) are cognitively toxic to aged patients while patients may tolerate non-anticholinergic selective serotonin re-uptake inhibitors (SSRIs) [<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The adverse effects of anticholinergic medications (AChs) have been extensively documented in both non-demented and demented populations [<xref rid='B23' ref-type='bibr'>23</xref>,<xref rid='B24' ref-type='bibr'>24</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Community-dwelling individuals using AChs are five times more likely to be classified as cognitively impaired compared to non-users; however, no excess risk of developing dementia was detected [<xref rid='B25' ref-type='bibr'>25</xref>].</s></p><p><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Due to a lack of evidence and contradictory trial results [<xref rid='B26' ref-type='bibr'>26</xref>], a systematic review did not recommend routine use of antiepileptics (AE) in treating the behavioral and psychological symptoms of dementia [<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Our literature search did not identify any studies on the use of opioids (Op) and modified risk of cognitive deterioration in cognitively disabled patients, nor have Op therapies for chronic pain among patients with dementia been studied [<xref rid='B27' ref-type='bibr'>27</xref>].</s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The analyses in the studies above, with the exception of one study [<xref rid='B12' ref-type='bibr'>12</xref>], only consider the use of a single drug type.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Consequently, the adverse effects of concomitant use of drugs with CNS effects on patients with pre-existing cognitive decline have not been explored.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, concomitant use of several kinds of drugs with CNS effects is common in pharmacotherapy for older patients [<xref rid='B28' ref-type='bibr'>28</xref>], especially among those with dementia [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a longitudinal study conducted in cognitively intact aged, the concomitant use of Ops and BZDs or Ops and any type of CNS medication was associated with the cognitive decline compared to non-users of these medications [<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> It can be hypothesized that the concomitant use of psychotropics or other drugs with CNS effects may have stronger negative effects on cognitive function than the use of a single drug with such effects.</s></p><p><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The aim of the present study was to describe and analyze the relationships between the use of a psychotropic (i.e. BZD, AP or AD), opioid, anticholinergic or antiepileptic drug or the concomitant use of two of these drugs, and the risk of precipitous cognitive decline in a population aged ≥65 years with deteriorated cognitive functioning at baseline.</s></p></sec><sec sec-type='methods' id='sec1_2'><title>Methods</title><sec id='sec2_1'><title>Participants and Data Collection</title><p><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>This study was part of a longitudinal population-based study performed in the municipality of Lieto, South-Western Finland [<xref rid='B31' ref-type='bibr'>31</xref>,<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The first phase of the Lieto study was carried out between October 1, 1990 and December 31, 1991, and the second phase between March 1, 1998 and September 31, 1999.</s></p><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The population of the first phase consisted of residents who were born in 1926 or earlier (n = 1,283).</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Of these, 1,196 (93%, 488 men and 708 women) participated.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The population of the second phase consisted of residents born in 1933 or earlier (n = 1,533) of whom 1,260 (82%) participated.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The validated Finnish version of the Mini-Mental State Examination (MMSE) [<xref rid='B33' ref-type='bibr'>33</xref>] was administered to all participants.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Its scale consists of 23 items, and the sum score ranges from 0 to 30, with higher scores indicating better cognitive performance.</s></p><p><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The population for the present longitudinal study was formed from those (i) who participated in the first phase and had a total score of 0–23 on the MMSE [<xref rid='B34' ref-type='bibr'>34</xref>], indicating deteriorated cognitive functioning, and (ii) who were alive and participated in the second phase.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The realized sample of the study population consisted of 52 residents (17 men and 35 women); the mean follow-up time was 7.6 ± 0.5 years (range: 6.6–8.7 years).</s></p><p><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>During both phases, proxies (relatives or caregivers) of the participants were interviewed for information on the participants’ socioeconomic background, physical and psychosocial factors and functional abilities, their use of drugs and health behavior(s).</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Participants were clinically examined by a health center physician belonging to the research team (R.I. or M.L.), and clinical tests were performed.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Medical records in the Härkätie Health Centre, Lieto, were used to record previously diagnosed diseases.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Similar processes were performed in both phases.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Cognitive abilities were measured by a trained nurse using the MMSE [<xref rid='B34' ref-type='bibr'>34</xref>] in both study phases.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Information about medication use was collected in the proxy interviews.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Subjects and their proxies had been requested to bring all of their prescription forms and drugs with them so that actual medication use could be confirmed.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All regularly or irregularly taken prescription drugs and non-prescribed drugs (e.g. vitamins) taken during the seven days prior to the interview were recorded.</s></p><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Drugs were defined by using the Anatomical Therapeutic Chemical (ATC) Classification [<xref rid='B35' ref-type='bibr'>35</xref>].</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The groups of drugs defined as having a CNS effect and therefore included in the analyses were: Ops (ATC codes N01AH, N02A, N02BE51, R05DA, R05FA), AChs (ATC codes N04A, N05AA01, N05AA02, N05AB01, N05AB02, N05AB03, N05AB04, N05AC01, N05AC02, N05AF01, N05AF03, N05AF05, N05BB01, N06AA04, N06AA06, N06AA09, N06AA12, 102AG, A03AA, A03AB, A03AX03, A03B, A03CA, A03CB31, A03DA, A03FA01, A04AD01, A04AD12, C01BA01, C01BA03, C01BA51, C01BA71, R03BB, M03B, G04BD, S01FA, R01BA01, R01BA51, R06AB01, R06AE03, R06AE53), AEs (ATC code N03A), BZDs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71), APs (ATC codes N05A, N06CA01), and ADs (ATC code N06A, N06CA).</s></p><p><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In both study phases, informed consent was obtained from every participant's relative or formal caregiver.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Plans for both the first and second Lieto studies were approved by the Joint Ethics Committee of the University of Turku and Turku University Central Hospital.</s></p></sec><sec id='sec2_2'><title>Statistical Analyses</title><p><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Statistical analyses were performed on the total population and separately by gender and age group (younger age group: 65–74 years; older age group: ≥75 years).</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Participants using a CNS medication at the beginning of the follow-up were compared (i) with participants who did not use any of these medications at baseline and (ii) with participants not using that specific medication.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Participants using a combination of two or more of the CNS medications were compared with participants using none of the individual CNS medications or their combinations.</s></p><p><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>χ<sup>2</sup> and Fisher's exact tests were used to test differences between genders and age groups, and between medication users and control groups at baseline and during the follow-up examination.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The statistical significance of differences in the use of medications between baseline and follow-up examination was analyzed with McNemar's test for every group of medications.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The significance of changes in MMSE total scores during the follow-up in the total population and in all subgroups was tested with the Wilcoxon signed rank test.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Differences between mean MMSE total scores and the changes of mean MMSE total scores between the groups were tested with the Mann-Whitney U test.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Associations between the use of a specific group of CNS medications or the use of a combination of CNS medications and the risk of cognitive decline were analyzed by the Mann-Whitney U test.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Significance of differences in cognitive functioning changes during the follow-up between the users of a certain group of CNS medications or the users of a combination of CNS medications and the corresponding control group of non-users was tested with the Mann-Whitney U test.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> As these are nonparametric tests, our analyses conservatively estimate realized p values.</s></p><p><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>After these analyses, adjusted analyses using analysis of covariance were performed for those groups in which the associations between the use of a certain CNS medication or the concomitant use of certain CNS medications and the risk for cognitive decline were either significant (p &lt; 0.05) or tending toward significant (0.05 &lt; p &lt; 0.10) in the bivariate analyses.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Associations between probable confounding variables (age, sex, education, hypertension, atrial fibrillation or flutter, diabetes mellitus, congestive heart disease and smoking at baseline) and the decline in MMSE total scores were analyzed in the total population.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> From these variables, higher age (p = 0.0007) was associated with a statistically significant decline in MMSE total scores.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Thus, only this variable was controlled as a confounding variable in the analyses of covariance.</s></p></sec></sec><sec sec-type='results' id='sec1_3'><title>Results</title><sec id='sec2_3'><title>Background Data</title><p><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Altogether 52 individuals participated in both phases of the study.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Their MMSE total scores at baseline ranged from 0 to 23 (indicating deteriorated cognitive functioning).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Fifteen (29%) were men and 37 (71%) women.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The majority (n = 30; 58%) were ≥75 years at the beginning of the follow-up, and 22 (42%) were 65–74 years old.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The mean age ± SD was 75.9 ± 7.2 years (range: 64–92).</s></p><p><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Altogether 15 participants (29%) lived at home with other people, 33 (63%) lived alone, and 4 (8%) were institutionalized.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Thirty-nine (76%) were able to walk independently, 10 (20%) with an assistive device, and 2 (4%) with the help of another person.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean number ± SD of prescribed medications used regularly was 2.8 ± 2.4, and that of drugs used irregularly (as needed) was 0.8 ± 1.1.</s></p></sec><sec id='sec2_4'><title>Use of Drugs at Baseline and during Follow-Up Examination</title><p><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>At baseline, BZDs and AChs were used by approximately every fifth participant (table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> APs, ADs and Ops were used by every tenth participant.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Half of the participants used at least one drug with effects on the CNS.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No differences in the use of these drugs were found between men and women.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Opioid use was more common among the older age group (20%) than among the younger one (0%) (p = 0.0328).</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Similarly, the use of at least one drug with effects on the CNS was more common among the older age group (63%) than among the younger one (23%) (p = 0.0051).</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The use of AD tended to be more common among the older age group than among the younger one but the difference did not achieve statistical significance.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The use of these drugs did not change significantly from baseline during the follow-up.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Ten to seventeen percent of the participants received concomitantly at least two drugs with effects on the CNS (table <xref rid='T2' ref-type='table'>2</xref>).</s></p></sec><sec id='sec2_5'><title>Cognitive Abilities at Baseline and Change by the Time of Follow-Up</title><p><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Cognitive functioning tended to decline in the total population and in all subgroups during the follow-up period, but the change was statistically significant only in the older age group (table <xref rid='T3' ref-type='table'>3</xref>).</s></p></sec><sec id='sec2_6'><title>Background Data and the Use of CNS Medications</title><p><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Users of CNS medications used more medications overall than did non-users, but the demographics between the two groups were similar (table <xref rid='T4' ref-type='table'>4</xref>).</s></p></sec><sec id='sec2_7'><title>Use of a Single Drug with CNS Effects as a Predictor of Cognitive Decline</title><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>After adjusting for confounding variables (age), the use of BZD or any psychotropic drug was still associated with the risk of cognitive decline in older (≥75 years) patients (table <xref rid='T5' ref-type='table'>5</xref>).</s></p></sec><sec id='sec2_8'><title>Concomitant Use of Two or More Drugs as a Predictor of Cognitive Decline</title><p><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>After adjusting for the confounding variable (age), concomitant use of BZD with AP or any drug with CNS effects was still associated with cognitive decline in the total population.</s></p><p><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Concomitant use of BZD and AD or ACh or any drug with CNS effects was associated with cognitive decline in the older population.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> These associations remained statistically significant after adjusting for the confounding variable (age).</s></p></sec></sec><sec sec-type='discussion' id='sec1_4'><title>Discussion</title><p><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>To our knowledge, this is the first longitudinal, population-based study describing and analyzing associations between concomitant use of drugs with effects on the CNS and the long-term risk of cognitive decline among cognitively disabled aged individuals.</s></p><p><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>We were able to show the association between use of any psychotropic drug and the risk of cognitive decline in a general population with pre-existing cognitive decline.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> We could also replicate the finding that BZD use predicts precipitous cognitive decline in a population with pre-existing cognitive decrements [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous studies have shown that the use of any psychotropic drug [<xref rid='B36' ref-type='bibr'>36</xref>] or, specifically, BZD [<xref rid='B37' ref-type='bibr'>37</xref>,<xref rid='B38' ref-type='bibr'>38</xref>,<xref rid='B39' ref-type='bibr'>39</xref>,<xref rid='B40' ref-type='bibr'>40</xref>] or BZD used concomitantly with Ops [<xref rid='B30' ref-type='bibr'>30</xref>] is associated with cognitive decline in a non-demented aged population.</s></p><p><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In our study, concomitant use of a BZD with an AD, an ACh, an AP or any drug with CNS effects predicted cognitive decline.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This is in line with the previous finding [<xref rid='B12' ref-type='bibr'>12</xref>] that concomitant use of a BZD and an AP is associated with precipitous cognitive decline.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Only one study [<xref rid='B12' ref-type='bibr'>12</xref>] has explored the effect of concomitant use of medications having CNS effects on cognitive function in a cognitively disabled population.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> That study, however, had a short follow-up period (12 months) and only included patients diagnosed with Alzheimer's disease, excluding patient groups with cognitive decline caused by other disorders.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Additionally, that study examined only the use of APs, BZDs and cholinergic medications in Alzheimer's disease.</s></p><p><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>It is obvious that the medications in the present study were used to treat the behavioral and psychological symptoms connected to declined cognition [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>,<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B8' ref-type='bibr'>8</xref>] in our sample.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The important question is whether the precipitous cognitive decline among those patients receiving medications with CNS effects was directly caused by the medications or is the result of a more aggressive dementing disorder with more difficult behavioral and psychological symptoms of dementia requiring medical treatment.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> However, in this sample only one participant was diagnosed with dementia and the other diagnosed conditions were not themselves cognitively progressive.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Thus, it is possible that the change in MMSE scores was directly caused by the medications.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> One placebo-controlled, randomized controlled trial [<xref rid='B13' ref-type='bibr'>13</xref>] supports the idea that AP use (in this study quetiapine, an atypical AP with some anticholinergic properties) increases the risk of hastened cognitive decline among patients with Alzheimer's disease, but it did not assess this risk with the concomitant use of other drugs.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Another randomized controlled trial found a risk of additional cognitive decline when Alzheimer patients with behavioral and psychological symptoms of dementia were treated with atypical APs (risperidone, quetiapine, olanzapine) compared to placebo [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The association between use of an ACh and cognitive decline has been previously shown in longitudinal epidemiologic studies among the aged [<xref rid='B25' ref-type='bibr'>25</xref>,<xref rid='B41' ref-type='bibr'>41</xref>,<xref rid='B42' ref-type='bibr'>42</xref>], but no such results have been published for a population with cognitive decline at baseline.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Only tricyclic ADs and conventional APs were used in our population in the beginning of the 1990s, and the strong anticholinergic properties of these medications, combined with the CNS-depressing GABAergic properties of BZDs may have mediated the detected cognitive adverse effects.</s></p><p><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Complete cognitive follow-up data were obtained for 52 participants.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The prospective, longitudinal design of this study is a major methodological strength.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A longitudinal population study such as the one we performed cannot directly show causalities, but it shows associations between certain factors and the risk of a harmful effect.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Many known risk factors (excluding the use of alcohol) could be adjusted for in our study.</s></p><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Our cohort consists of an older general population with cognitive decline.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The participation rates were high in both phases of the Lieto study.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Medication history and clinical background data were recorded reliably.</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The measure of cognitive functioning (MMSE, a measure of general cognitive performance) is a frequently used, validated instrument for assessing global cognitive functioning.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Only participants who had a MMSE total score of 0–23, indicating cognitive decline at baseline, were included in the present study.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The MMSE cut-off point of 24/23 provides a sensitivity of 69% and a specificity of 99% for dementia [<xref rid='B43' ref-type='bibr'>43</xref>].</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Data on cognitive change were available only for individuals who were alive and participated in both phases.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The difference in the number of subjects between Phase 1 and Phase 2 is accounted for by individuals who had died during the follow-up period, refused to participate, or were lost to follow-up.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> We adjusted the results for several known risk factors of cognitive decline, but co-existing medical or other conditions or behaviors (e.g. the use of alcohol) may also be related to cognitive decline.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Alcohol use was not measured during the first phase, therefore we could not use it as a confounding variable.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, in our population only one subject had a diagnosis of excessive alcohol use.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous studies on alcohol use among Finns have shown that it diminishes with increasing age.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A previous study found only a few older individuals who were classified as frequent users and who drank large quantities of alcohol [<xref rid='B44' ref-type='bibr'>44</xref>].</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In our study, the majority of participants (13 of 15 men and 35 of 37 women) were living at home at baseline.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> During the follow-up, no men, but 13 of 37 women were institutionalized.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We suggest that the material did not include current heavy users of alcohol.</s></p><p><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>During the early 1990s, it was rare for aged Finns to receive medications with CNS effects.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The concomitant use of several drugs with CNS effects was even rarer.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These facts influence the power of the statistical tests, especially in analyzing the data adjusted for gender and age.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Drug use categories were determined by the data from the first phase of the study.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Additional drugs may have been started and previous ones may have been discontinued during the follow-up.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, many of these kinds of drugs are prescribed on a long-term basis, for many years among the aged in Finland, even against recommendations (e.g. BZD) [<xref rid='B45' ref-type='bibr'>45</xref>].</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The great majority of medications in the study population were used on a long-term basis.</s></p><p><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>No cholinergic medication for Alzheimer's disease was approved for marketing during the study period, and therefore, this category could not be analyzed.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Only conventional APs were available in the beginning of the 1990s; thus, differences between conventional and atypical APs could not be studied either.</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Tricyclic ADs were the only class of ADs used, meaning that no comparison between tricyclic ADs and newer ADs (e.g. SSRI) was possible.</s></p><p><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The number of individuals using two or more medications with CNS effects concomitantly was low.</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This poses statistical limitations.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Negative results may be caused by the rather small sample size and the small number of users.</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Due to a lack of statistical power, the results do not prove that medications with CNS effects have a negative effect on cognition.</s><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Positive results, especially measured by the quite insensitive MMSE, however, show strong associations in this population.</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Based on the results from the present study, prescribing two or more medications with CNS effects to cognitively disabled older individuals should be based on a critical, individualized assessment.</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The cognitively disabled requiring treatment with multiple psychotropics should be carefully monitored to permit earlier detection of the precipitous cognitive decline associated with the use of these medications.</s></p></sec><sec sec-type='conclusions' id='sec1_5'><title>Conclusions</title><p><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>The use of a BZD or any psychotropic medication may be an independent risk factor for further cognitive decline in the cognitively disabled aged.</s><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The concomitant use of a BZD and an AP, an AD, an ACh or any CNS-affecting medication poses a higher risk of precipitous cognitive decline.</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, studies with larger sample sizes and studies on possible pathophysiologic mechanisms are needed to develop a more complete understanding of these phenomena.</s></p></sec><sec id='sec1_6'><title>Disclosure Statement</title><p>This study was financially supported by the 19th February Fund of the Finnish Heart Association; the Finnish Academy; the Federation of Municipalities of Härkätie, Lieto, Finland; Turku University Hospital Grant EVO; Satakunta Hospital District Grant EVO; the Finnish Association for General Practice; the Uulo Arhio Foundation; and the Finnish Cultural Foundation.</p><p>J.P. has lectured in continuing education courses for physicians, nurses and physiotherapists sponsored by Janssen-Cilag, Lundbeck and Novartis. J.N., T.V. and R.I. have no competing interests. I.R. has given lectures in continuing education courses for physicians and nurses sponsored by Novartis and Janssen-Cilag. S.-L.K. has given lectures in continuing education courses for physicians, nurses and physiotherapists sponsored by Janssen-Cilag, Pfizer, Lundbeck, Novartis, Leiras and ratiopharm.</p><p>All authors of the article are independent from funders and have no conflicts of interest. The financial sponsors played no role in the design, execution, analysis or interpretation of data or in preparing the manuscript.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank Health Centre physician Dr. Minna Löppönen, MD, PhD, for her substantial contribution in collecting data in the second phase of the study, ADP Designers Jukka Saukkoriipi and Teemu Kemppainen for their valuable work in performing the statistical analyses, and Project Secretary Selena Nitecki for her assistance in the writing process.</p></ack><ref-list><title>References</title><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wragg</surname><given-names>RE</given-names></name><name><surname>Jeste</surname><given-names>DV</given-names></name></person-group><article-title>Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions</article-title><source>Psychiatr Clin North Am</source><year>1988</year><volume>11</volume><fpage>195</fpage><lpage>213</lpage><pub-id pub-id-type='pmid'>2898133</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Semla</surname><given-names>TP</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Freels</surname><given-names>S</given-names></name><name><surname>Paveza</surname><given-names>GJ</given-names></name><name><surname>Ashford</surname><given-names>JW</given-names></name><name><surname>Gorelick</surname><given-names>P</given-names></name><name><surname>Luchins</surname><given-names>D</given-names></name><name><surname>Eisdorfer</surname><given-names>C</given-names></name></person-group><article-title>Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease</article-title><source>Pharmacotherapy</source><year>1995</year><volume>15</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type='pmid'>7479203</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Burke</surname><given-names>WJ</given-names></name><name><surname>Dewan</surname><given-names>V</given-names></name><name><surname>Wengel</surname><given-names>SP</given-names></name><name><surname>Roccaforte</surname><given-names>WH</given-names></name><name><surname>Nadolny</surname><given-names>GC</given-names></name><name><surname>Folks</surname><given-names>DG</given-names></name></person-group><article-title>The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia</article-title><source>Int J Geriatr Psychiatry</source><year>1997</year><volume>12</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type='pmid'>9193959</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Stern</surname><given-names>RG</given-names></name><name><surname>Duffelmeyer</surname><given-names>ME</given-names></name><name><surname>Zemishlani</surname><given-names>Z</given-names></name><name><surname>Davidson</surname><given-names>M</given-names></name></person-group><article-title>The use of benzodiazepines in the management of behavioral symptoms in demented patients</article-title><source>Psychiatr Clin North Am</source><year>1991</year><volume>14</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type='pmid'>1676508</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lemke</surname><given-names>MR</given-names></name></person-group><article-title>Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics</article-title><source>J Clin Psychiatry</source><year>1995</year><volume>56</volume><fpage>354</fpage><lpage>357</lpage><pub-id pub-id-type='pmid'>7635851</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Erb</surname><given-names>R</given-names></name><name><surname>Podgorski</surname><given-names>CA</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Jakimovich</surname><given-names>L</given-names></name><name><surname>Irvine</surname><given-names>C</given-names></name></person-group><article-title>Efficacy and tolerability of carbamazepine for agitation and aggression in dementia</article-title><source>Am J Psychiatry</source><year>1998</year><volume>155</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type='pmid'>9433339</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Erb</surname><given-names>R</given-names></name><name><surname>Gaile</surname><given-names>S</given-names></name></person-group><article-title>An open trial of valproate for agitation in geriatric neuropsychiatric disorders</article-title><source>Am J Geriatr Psychiatry</source><year>1997</year><volume>5</volume><fpage>344</fpage><lpage>351</lpage><pub-id pub-id-type='pmid'>9363292</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Finkel</surname><given-names>SI</given-names></name><name><surname>Costa e Silva</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>S</given-names></name><name><surname>Sartorius</surname><given-names>N</given-names></name></person-group><article-title>Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment</article-title><source>Int Psychogeriatr</source><year>1996</year><volume>8</volume><issue>suppl 3</issue><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type='pmid'>9154615</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jeste</surname><given-names>DV</given-names></name><name><surname>Caligiuri</surname><given-names>MP</given-names></name><name><surname>Paulsen</surname><given-names>JS</given-names></name><name><surname>Heaton</surname><given-names>RK</given-names></name><name><surname>Lacro</surname><given-names>JP</given-names></name><name><surname>Harris</surname><given-names>MJ</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Fell</surname><given-names>RL</given-names></name><name><surname>McAdams</surname><given-names>LA</given-names></name></person-group><article-title>Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients</article-title><source>Arch Gen Psychiatry</source><year>1995</year><volume>52</volume><fpage>756</fpage><lpage>765</lpage><pub-id pub-id-type='pmid'>7654127</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sultzer</surname><given-names>DL</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Dagerman</surname><given-names>KS</given-names></name><name><surname>Lebowitz</surname><given-names>BD</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name><name><surname>Hsiao</surname><given-names>JK</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name></person-group><article-title>Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial</article-title><source>Am J Psychiatry</source><year>2008</year><volume>165</volume><fpage>844</fpage><lpage>854</lpage><pub-id pub-id-type='pmid'>18519523</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Keene</surname><given-names>J</given-names></name><name><surname>Gedling</surname><given-names>K</given-names></name><name><surname>Fairburn</surname><given-names>C</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name><name><surname>Hope</surname><given-names>T</given-names></name></person-group><article-title>Do neuroleptic drugs hasten cognitive decline in dementia?</article-title><source>Prospective study with necropsy follow up. BMJ</source><year>1997</year><volume>314</volume><fpage>266</fpage><lpage>270</lpage></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ellul</surname><given-names>J</given-names></name><name><surname>Archer</surname><given-names>N</given-names></name><name><surname>Foy</surname><given-names>CM</given-names></name><name><surname>Poppe</surname><given-names>M</given-names></name><name><surname>Boothby</surname><given-names>H</given-names></name><name><surname>Nicholas</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name></person-group><article-title>The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type='pmid'>17012333</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Margallo-Lana</surname><given-names>M</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Douglas</surname><given-names>S</given-names></name><name><surname>Swann</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>O'brien</surname><given-names>J</given-names></name><name><surname>Everratt</surname><given-names>A</given-names></name><name><surname>Sadler</surname><given-names>S</given-names></name><name><surname>Maddison</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Bannister</surname><given-names>C</given-names></name><name><surname>Elvish</surname><given-names>R</given-names></name><name><surname>Jacoby</surname><given-names>R</given-names></name></person-group><article-title>Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial</article-title><source>BMJ</source><year>2005</year><volume>330</volume><fpage>874</fpage><pub-id pub-id-type='pmid'>15722369</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Vigen</surname><given-names>CL</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name><name><surname>Keefe</surname><given-names>RS</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Sultzer</surname><given-names>DL</given-names></name><name><surname>Stroup</surname><given-names>TS</given-names></name><name><surname>Dagerman</surname><given-names>KS</given-names></name><name><surname>Hsiao</surname><given-names>JK</given-names></name><name><surname>Lebowitz</surname><given-names>BD</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name></person-group><article-title>Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD</article-title><source>Am J Psychiatry</source><year>2011</year><volume>168</volume><fpage>831</fpage><lpage>839</lpage><pub-id pub-id-type='pmid'>21572163</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>AE</given-names></name><name><surname>Katona</surname><given-names>CL</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name></person-group><article-title>Antipsychotics and cognitive decline in Alzheimer's disease: The LASER-Alzheimer's disease longitudinal study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type='pmid'>16801350</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Boller</surname><given-names>F</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name></person-group><article-title>Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>1266</fpage><lpage>1272</lpage><pub-id pub-id-type='pmid'>10520944</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rocca</surname><given-names>P</given-names></name><name><surname>Marino</surname><given-names>F</given-names></name><name><surname>Montemagni</surname><given-names>C</given-names></name><name><surname>Perrone</surname><given-names>D</given-names></name><name><surname>Bogetto</surname><given-names>F</given-names></name></person-group><article-title>Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study</article-title><source>Psychiatry Clin Neurosci</source><year>2007</year><volume>61</volume><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type='pmid'>18081622</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Caballero</surname><given-names>J</given-names></name><name><surname>Hitchcock</surname><given-names>M</given-names></name><name><surname>Scharre</surname><given-names>D</given-names></name><name><surname>Beversdorf</surname><given-names>D</given-names></name><name><surname>Nahata</surname><given-names>MC</given-names></name></person-group><article-title>Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study</article-title><source>Clin Ther</source><year>2006</year><volume>28</volume><fpage>1695</fpage><lpage>1700</lpage><pub-id pub-id-type='pmid'>17157125</pub-id></element-citation></ref><ref id='B19'><label>19</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rainer</surname><given-names>MK</given-names></name><name><surname>Masching</surname><given-names>AJ</given-names></name><name><surname>Ertl</surname><given-names>MG</given-names></name><name><surname>Kraxberger</surname><given-names>E</given-names></name><name><surname>Haushofer</surname><given-names>M</given-names></name></person-group><article-title>Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type='pmid'>11775050</pub-id></element-citation></ref><ref id='B20'><label>20</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rainer</surname><given-names>M</given-names></name><name><surname>Haushofer</surname><given-names>M</given-names></name><name><surname>Pfolz</surname><given-names>H</given-names></name><name><surname>Struhal</surname><given-names>C</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name></person-group><article-title>Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function</article-title><source>Eur Psychiatry</source><year>2007</year><volume>22</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type='pmid'>17482432</pub-id></element-citation></ref><ref id='B21'><label>21</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Katz</surname><given-names>IR</given-names></name><name><surname>Brodaty</surname><given-names>H</given-names></name><name><surname>Lyons</surname><given-names>B</given-names></name><name><surname>Greenspan</surname><given-names>A</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name></person-group><article-title>Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone</article-title><source>Clin Neurol Neurosurg</source><year>2005</year><volume>107</volume><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type='pmid'>15922506</pub-id></element-citation></ref><ref id='B22'><label>22</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Oxman</surname><given-names>TE</given-names></name></person-group><article-title>Antidepressants and cognitive impairment in the elderly</article-title><source>J Clin Psychiatry</source><year>1996</year><volume>57</volume><issue>suppl 5</issue><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type='pmid'>8647791</pub-id></element-citation></ref><ref id='B23'><label>23</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Kaduszkiewicz</surname><given-names>H</given-names></name><name><surname>Daerr</surname><given-names>M</given-names></name><name><surname>Bickel</surname><given-names>H</given-names></name><name><surname>Pentzek</surname><given-names>M</given-names></name><name><surname>Riedel-Heller</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Weyerer</surname><given-names>S</given-names></name><name><surname>Wiese</surname><given-names>B</given-names></name><name><surname>van den Bussche</surname><given-names>H</given-names></name><name><surname>Broich</surname><given-names>K</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name></person-group><article-title>Anticholinergic drug use and risk for dementia: target for dementia prevention</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2010</year><volume>260</volume><issue>suppl 2</issue><fpage>S111</fpage><lpage>S115</lpage><pub-id pub-id-type='pmid'>20960005</pub-id></element-citation></ref><ref id='B24'><label>24</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sittironnarit</surname><given-names>G</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name><name><surname>Bush</surname><given-names>AI</given-names></name><name><surname>Faux</surname><given-names>N</given-names></name><name><surname>Flicker</surname><given-names>L</given-names></name><name><surname>Foster</surname><given-names>J</given-names></name><name><surname>Hilmer</surname><given-names>S</given-names></name><name><surname>Lautenschlager</surname><given-names>NT</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Martins</surname><given-names>RN</given-names></name><name><surname>Rowe</surname><given-names>C</given-names></name><name><surname>Szoeke</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>KA</given-names></name></person-group><article-title>Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>31</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type='pmid'>21389718</pub-id></element-citation></ref><ref id='B25'><label>25</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ancelin</surname><given-names>ML</given-names></name><name><surname>Artero</surname><given-names>S</given-names></name><name><surname>Portet</surname><given-names>F</given-names></name><name><surname>Dupuy</surname><given-names>AM</given-names></name><name><surname>Touchon</surname><given-names>J</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name></person-group><article-title>Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type='pmid'>16452102</pub-id></element-citation></ref><ref id='B26'><label>26</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Konovalov</surname><given-names>S</given-names></name><name><surname>Muralee</surname><given-names>S</given-names></name><name><surname>Tampi</surname><given-names>RR</given-names></name></person-group><article-title>Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review</article-title><source>Int Psychogeriatr</source><year>2008</year><volume>20</volume><fpage>293</fpage><lpage>308</lpage><pub-id pub-id-type='pmid'>18047764</pub-id></element-citation></ref><ref id='B27'><label>27</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lorenz</surname><given-names>KA</given-names></name><name><surname>Lynn</surname><given-names>J</given-names></name><name><surname>Dy</surname><given-names>SM</given-names></name><name><surname>Shugarman</surname><given-names>LR</given-names></name><name><surname>Wilkinson</surname><given-names>A</given-names></name><name><surname>Mularski</surname><given-names>RA</given-names></name><name><surname>Morton</surname><given-names>SC</given-names></name><name><surname>Hughes</surname><given-names>RG</given-names></name><name><surname>Hilton</surname><given-names>LK</given-names></name><name><surname>Maglione</surname><given-names>M</given-names></name><name><surname>Rhodes</surname><given-names>SL</given-names></name><name><surname>Rolon</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>VC</given-names></name><name><surname>Shekelle</surname><given-names>PG</given-names></name></person-group><article-title>Evidence for improving palliative care at the end of life: a systematic review</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type='pmid'>18195339</pub-id></element-citation></ref><ref id='B28'><label>28</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hartikainen</surname><given-names>S</given-names></name><name><surname>Mantyselka</surname><given-names>P</given-names></name><name><surname>Louhivuori-Laako</surname><given-names>K</given-names></name><name><surname>Enlund</surname><given-names>H</given-names></name><name><surname>Sulkava</surname><given-names>R</given-names></name></person-group><article-title>Concomitant use of analgesics and psychotropics in home-dwelling elderly people-kuopio 75 + study</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>60</volume><fpage>306</fpage><lpage>310</lpage><pub-id pub-id-type='pmid'>16120070</pub-id></element-citation></ref><ref id='B29'><label>29</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pitkala</surname><given-names>KH</given-names></name><name><surname>Laurila</surname><given-names>JV</given-names></name><name><surname>Strandberg</surname><given-names>TE</given-names></name><name><surname>Tilvis</surname><given-names>RS</given-names></name></person-group><article-title>Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards</article-title><source>Int Psychogeriatr</source><year>2004</year><volume>16</volume><fpage>61</fpage><lpage>74</lpage><pub-id pub-id-type='pmid'>15190997</pub-id></element-citation></ref><ref id='B30'><label>30</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Puustinen</surname><given-names>J</given-names></name><name><surname>Nurminen</surname><given-names>J</given-names></name><name><surname>Lopponen</surname><given-names>M</given-names></name><name><surname>Vahlberg</surname><given-names>T</given-names></name><name><surname>Isoaho</surname><given-names>R</given-names></name><name><surname>Raiha</surname><given-names>I</given-names></name><name><surname>Kivela</surname><given-names>SL</given-names></name></person-group><article-title>Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study</article-title><source>BMC Geriatr</source><year>2011</year><volume>11</volume><fpage>70</fpage><pub-id pub-id-type='pmid'>22044595</pub-id></element-citation></ref><ref id='B31'><label>31</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Isoaho</surname><given-names>R</given-names></name><name><surname>Puolijoki</surname><given-names>H</given-names></name><name><surname>Huhti</surname><given-names>E</given-names></name><name><surname>Kivela</surname><given-names>SL</given-names></name><name><surname>Tala</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of asthma in elderly Finns</article-title><source>J Clin Epidemiol</source><year>1994</year><volume>47</volume><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type='pmid'>7722544</pub-id></element-citation></ref><ref id='B32'><label>32</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lopponen</surname><given-names>M</given-names></name><name><surname>Raiha</surname><given-names>I</given-names></name><name><surname>Isoaho</surname><given-names>R</given-names></name><name><surname>Vahlberg</surname><given-names>T</given-names></name><name><surname>Kivela</surname><given-names>SL</given-names></name></person-group><article-title>Diagnosing cognitive impairment and dementia in primary health care – a more active approach is needed</article-title><source>Age Ageing</source><year>2003</year><volume>32</volume><fpage>606</fpage><lpage>612</lpage><pub-id pub-id-type='pmid'>14600001</pub-id></element-citation></ref><ref id='B33'><label>33</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Riekkinen</surname><given-names>PJ</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name></person-group><article-title>Cross-cultural studies of dementia. A comparison of mini-mental state examination performance in Finland and China</article-title><source>Arch Neurol</source><year>1989</year><volume>46</volume><fpage>769</fpage><lpage>772</lpage><pub-id pub-id-type='pmid'>2742548</pub-id></element-citation></ref><ref id='B34'><label>34</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='pmid'>1202204</pub-id></element-citation></ref><ref id='B35'><label>35</label><element-citation publication-type='book'><source>Classification of Medicines (ATC) and Defined Daily Doses (DDD)</source><year>1991</year><publisher-loc>Helsinki, Finland</publisher-loc><publisher-name>National Agency of Medicines</publisher-name></element-citation></ref><ref id='B36'><label>36</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Berg</surname><given-names>S</given-names></name><name><surname>Dellasega</surname><given-names>C</given-names></name></person-group><article-title>The use of psychoactive medications and cognitive function in older adults</article-title><source>J Aging Health</source><year>1996</year><volume>8</volume><fpage>136</fpage><lpage>149</lpage><pub-id pub-id-type='pmid'>10160568</pub-id></element-citation></ref><ref id='B37'><label>37</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hanlon</surname><given-names>JT</given-names></name><name><surname>Horner</surname><given-names>RD</given-names></name><name><surname>Schmader</surname><given-names>KE</given-names></name><name><surname>Fillenbaum</surname><given-names>GG</given-names></name><name><surname>Lewis</surname><given-names>IK</given-names></name><name><surname>Wall</surname><given-names>WE</given-names><suffix>Jr</suffix></name><name><surname>Landerman</surname><given-names>LR</given-names></name><name><surname>Pieper</surname><given-names>CF</given-names></name><name><surname>Blazer</surname><given-names>DG</given-names></name><name><surname>Cohen</surname><given-names>HJ</given-names></name></person-group><article-title>Benzodiazepine use and cognitive function among community-dwelling elderly</article-title><source>Clin Pharmacol Ther</source><year>1998</year><volume>64</volume><fpage>684</fpage><lpage>692</lpage><pub-id pub-id-type='pmid'>9871433</pub-id></element-citation></ref><ref id='B38'><label>38</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lagnaoui</surname><given-names>R</given-names></name><name><surname>Begaud</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>N</given-names></name><name><surname>Chaslerie</surname><given-names>A</given-names></name><name><surname>Fourrier</surname><given-names>A</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Moride</surname><given-names>Y</given-names></name></person-group><article-title>Benzodiazepine use and risk of dementia: a nested case-control study</article-title><source>J Clin Epidemiol</source><year>2002</year><volume>55</volume><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type='pmid'>11864804</pub-id></element-citation></ref><ref id='B39'><label>39</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Paterniti</surname><given-names>S</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Alperovitch</surname><given-names>A</given-names></name></person-group><article-title>Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study</article-title><source>J Clin Psychopharmacol</source><year>2002</year><volume>22</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type='pmid'>12006899</pub-id></element-citation></ref><ref id='B40'><label>40</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bierman</surname><given-names>EJ</given-names></name><name><surname>Comijs</surname><given-names>HC</given-names></name><name><surname>Gundy</surname><given-names>CM</given-names></name><name><surname>Sonnenberg</surname><given-names>C</given-names></name><name><surname>Jonker</surname><given-names>C</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name></person-group><article-title>The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent?</article-title><source>Int J Geriatr Psychiatry</source><year>2007</year><volume>22</volume><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type='pmid'>17407168</pub-id></element-citation></ref><ref id='B41'><label>41</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bottiggi</surname><given-names>KA</given-names></name><name><surname>Salazar</surname><given-names>JC</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Caban-Holt</surname><given-names>AM</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Mendiondo</surname><given-names>MS</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name></person-group><article-title>Long-term cognitive impact of anticholinergic medications in older adults</article-title><source>Am J Geriatr Psychiatry</source><year>2006</year><volume>14</volume><fpage>980</fpage><lpage>984</lpage><pub-id pub-id-type='pmid'>17068321</pub-id></element-citation></ref><ref id='B42'><label>42</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Knegtering</surname><given-names>H</given-names></name><name><surname>Eijck</surname><given-names>M</given-names></name><name><surname>Huijsman</surname><given-names>A</given-names></name></person-group><article-title>Effects of antidepressants on cognitive functioning of elderly patients. A review</article-title><source>Drugs Aging</source><year>1994</year><volume>5</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type='pmid'>7803947</pub-id></element-citation></ref><ref id='B43'><label>43</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tangalos</surname><given-names>EG</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Ivnik</surname><given-names>RJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Kokmen</surname><given-names>E</given-names></name><name><surname>Kurland</surname><given-names>LT</given-names></name><name><surname>Offord</surname><given-names>KP</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name></person-group><article-title>The mini-mental state examination in general medical practice: clinical utility and acceptance</article-title><source>Mayo Clin Proc</source><year>1996</year><volume>71</volume><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type='pmid'>8790257</pub-id></element-citation></ref><ref id='B44'><label>44</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kivela</surname><given-names>SL</given-names></name><name><surname>Nissinen</surname><given-names>A</given-names></name><name><surname>Ketola</surname><given-names>A</given-names></name><name><surname>Punsar</surname><given-names>S</given-names></name><name><surname>Puska</surname><given-names>P</given-names></name><name><surname>Karvonen</surname><given-names>M</given-names></name></person-group><article-title>Changes in alcohol consumption during a ten-year follow-up among Finnish men aged 55–74 years</article-title><source>Funct Neurol</source><year>1988</year><volume>3</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type='pmid'>3402816</pub-id></element-citation></ref><ref id='B45'><label>45</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Puustinen</surname><given-names>J</given-names></name><name><surname>Nurminen</surname><given-names>J</given-names></name><name><surname>Kukola</surname><given-names>M</given-names></name><name><surname>Vahlberg</surname><given-names>T</given-names></name><name><surname>Laine</surname><given-names>K</given-names></name><name><surname>Kivela</surname><given-names>SL</given-names></name></person-group><article-title>Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly</article-title><source>Drugs Aging</source><year>2007</year><volume>24</volume><fpage>1045</fpage><lpage>1059</lpage><pub-id pub-id-type='pmid'>18020536</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap orientation='portrait' id='T1' position='float'><label>Table 1</label><caption><p>Single and concomitant use of drugs with CNS effects at baseline, at follow-up examination and at both times in a population aged ≥65 years with an MMSE total score of 0–23</p></caption><table rules='groups' frame='hsides'><thead><tr valign='bottom'><th colspan='1' rowspan='1' align='left'></th><th colspan='2' rowspan='1' align='left'>Baseline (n = 52)</th><th colspan='2' rowspan='1' align='left'>Follow-up (n = 52)</th><th colspan='2' rowspan='1' align='left'>Both at baseline and follow-up (n = 52)</th></tr><tr><th colspan='7' rowspan='1'><hr></hr></th></tr><tr valign='top'><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>n</th><th colspan='1' rowspan='1' align='left'>%</th><th colspan='1' rowspan='1' align='left'>n</th><th colspan='1' rowspan='1' align='left'>%</th><th colspan='1' rowspan='1' align='left'>n</th><th colspan='1' rowspan='1' align='left'>%</th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Ops</td><td colspan='1' rowspan='1' align='left'>6</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>6</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>4</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>AChs</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>23</td><td colspan='1' rowspan='1' align='left'>14</td><td colspan='1' rowspan='1' align='left'>27</td><td colspan='1' rowspan='1' align='left'>8</td><td colspan='1' rowspan='1' align='left'>15</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>APs</td><td colspan='1' rowspan='1' align='left'>6</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>8</td><td colspan='1' rowspan='1' align='left'>15</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>8</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>ADs</td><td colspan='1' rowspan='1' align='left'>5</td><td colspan='1' rowspan='1' align='left'>10</td><td colspan='1' rowspan='1' align='left'>9</td><td colspan='1' rowspan='1' align='left'>17</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>8</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>BZDs</td><td colspan='1' rowspan='1' align='left'>11</td><td colspan='1' rowspan='1' align='left'>21</td><td colspan='1' rowspan='1' align='left'>15</td><td colspan='1' rowspan='1' align='left'>29</td><td colspan='1' rowspan='1' align='left'>7</td><td colspan='1' rowspan='1' align='left'>13</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>AEs</td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>2</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>At least one of the above drugs</td><td colspan='1' rowspan='1' align='left'>24</td><td colspan='1' rowspan='1' align='left'>46</td><td colspan='1' rowspan='1' align='left'>29</td><td colspan='1' rowspan='1' align='left'>56</td><td colspan='1' rowspan='1' align='left'>8</td><td colspan='1' rowspan='1' align='left'>15</td></tr></tbody></table></table-wrap><table-wrap orientation='portrait' id='T2' position='float'><label>Table 2</label><caption><p>Concomitant use of drugs with CNS effects by drug combinations in a population aged ≥65 years at baseline with pre-existing cognitive decline (MMSE score 0–23)</p></caption><table rules='groups' frame='hsides'><thead><tr valign='bottom'><th colspan='1' rowspan='1' align='left'>Combinations of medications</th><th colspan='1' rowspan='1' align='left'>n (total = 52)</th><th colspan='1' rowspan='1' align='left'>%</th></tr></thead><tbody><tr valign='top'><td colspan='3' rowspan='1' align='left'>Op <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>ACh</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>4</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AE</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>BZD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>2</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AP</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>4</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>3</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>8</td></tr><tr valign='top'><td colspan='3' rowspan='1' align='left'>ACh <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AE</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>BZD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>3</td><td colspan='1' rowspan='1' align='left'>6</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AP</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>8</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>3</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>9</td><td colspan='1' rowspan='1' align='left'>17</td></tr><tr valign='top'><td colspan='3' rowspan='1' align='left'>AE <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>BZD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AP</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0</td><td colspan='1' rowspan='1' align='left'>0</td></tr><tr valign='top'><td colspan='3' rowspan='1' align='left'>BZD <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AP</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>2</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>3</td><td colspan='1' rowspan='1' align='left'>6</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>5</td><td colspan='1' rowspan='1' align='left'>10</td></tr><tr valign='top'><td colspan='3' rowspan='1' align='left'>AP <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>4</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>6</td><td colspan='1' rowspan='1' align='left'>12</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>AD <italic>and</italic></td><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any of the above drugs</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>5</td><td colspan='1' rowspan='1' align='left'>10</td></tr></tbody></table></table-wrap><table-wrap orientation='portrait' id='T3' position='float'><label>Table 3</label><caption><p>Cognitive functioning measured by MMSE at baseline and at a 7.6-year follow-up, by gender and age</p></caption><table rules='groups' frame='hsides'><thead><tr valign='bottom'><th colspan='1' rowspan='1' align='left'>Population</th><th colspan='2' rowspan='1' align='left'>MMSE sum score</th><th colspan='1' rowspan='1' align='left'>p value<xref rid='T3F1' ref-type='table-fn'><sup>*</sup></xref></th></tr><tr><th colspan='4' rowspan='1'><hr></hr></th></tr><tr valign='top'><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>at baseline (1990–1991)</th><th colspan='1' rowspan='1' align='left'>during follow-up (1998–1999)</th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Total population</td><td colspan='1' rowspan='1' align='left'>20.0 ± 5.5</td><td colspan='1' rowspan='1' align='left'>17.9 ± 8.8</td><td colspan='1' rowspan='1' align='left'>0.129</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Men</td><td colspan='1' rowspan='1' align='left'>19.3 ± 6.3</td><td colspan='1' rowspan='1' align='left'>15.7 ± 7.5</td><td colspan='1' rowspan='1' align='left'>0.102</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Women</td><td colspan='1' rowspan='1' align='left'>20.4 ± 5.2</td><td colspan='1' rowspan='1' align='left'>18.8 ± 9.2</td><td colspan='1' rowspan='1' align='left'>0.406</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>At baseline 65–74 years</td><td colspan='1' rowspan='1' align='left'>21.9 ± 2.4</td><td colspan='1' rowspan='1' align='left'>22.3 ± 7.8</td><td colspan='1' rowspan='1' align='left'>0.341</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>At baseline ≥75 years</td><td colspan='1' rowspan='1' align='left'>18.7 ± 6.6</td><td colspan='1' rowspan='1' align='left'>14.7 ± 8.2</td><td colspan='1' rowspan='1' align='left'>0.003</td></tr></tbody></table><table-wrap-foot><fn><p>Values denote means ± SD.</p></fn><fn id='T3F1'><label>*</label><p>Wilcoxon signed rank test.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T4' position='float'><label>Table 4</label><caption><p>Background data on the use of medications with CNS effects and significance of the differences between users of these drugs and non-users at baseline</p></caption><table rules='groups' frame='hsides'><thead><tr valign='bottom'><th colspan='1' rowspan='1' align='left'>Background variable</th><th colspan='1' rowspan='1' align='left'>Users (n = 24)</th><th colspan='1' rowspan='1' align='left'>Non-users (n = 28)</th><th colspan='1' rowspan='1' align='left'>p value</th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>Age, years</td><td colspan='1' rowspan='1' align='left'>77.8 ± 6.6</td><td colspan='1' rowspan='1' align='left'>74.4 ± 7.5</td><td colspan='1' rowspan='1' align='left'>0.114<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of all medications</td><td colspan='1' rowspan='1' align='left'>5.4 ± 3.2</td><td colspan='1' rowspan='1' align='left'>2.1 ± 2.1</td><td colspan='1' rowspan='1' align='left'>&lt; 0.001<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of regularly taken medications</td><td colspan='1' rowspan='1' align='left'>4.2 ± 2.4</td><td colspan='1' rowspan='1' align='left'>1.7 ± 1.6</td><td colspan='1' rowspan='1' align='left'>&lt; 0.001<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of medications taken as needed</td><td colspan='1' rowspan='1' align='left'>1.2 ± 1.4</td><td colspan='1' rowspan='1' align='left'>0.4 ± 0.7</td><td colspan='1' rowspan='1' align='left'>0.016<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of all medications excluding CNS medications</td><td colspan='1' rowspan='1' align='left'>3.9 ± 2.9</td><td colspan='1' rowspan='1' align='left'>2.1 ± 2.1</td><td colspan='1' rowspan='1' align='left'>0.021<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of regularly taken medications excluding CNS medications</td><td colspan='1' rowspan='1' align='left'>3.1 ± 2.2</td><td colspan='1' rowspan='1' align='left'>1.7 ± 1.6</td><td colspan='1' rowspan='1' align='left'>0.017<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Number of medications taken as needed excluding CNS medications</td><td colspan='1' rowspan='1' align='left'>0.8 ± 1.2</td><td colspan='1' rowspan='1' align='left'>0.4 ± 0.7</td><td colspan='1' rowspan='1' align='left'>0.262<xref rid='T4F1' ref-type='table-fn'><sup>*</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Females</td><td colspan='1' rowspan='1' align='left'>5 (21)</td><td colspan='1' rowspan='1' align='left'>10 (36)</td><td colspan='1' rowspan='1' align='left'>0.238<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='4' rowspan='1' align='left'>Marital status</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Married</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>4 (17)</td><td colspan='1' rowspan='1' align='left'>5 (18)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Unmarried or divorced</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>8 (33)</td><td colspan='1' rowspan='1' align='left'>15 (54)</td><td colspan='1' rowspan='1' align='left'>0.250<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Widowed</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>12 (50)</td><td colspan='1' rowspan='1' align='left'>8 (29)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='4' rowspan='1' align='left'>Place of living</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>At home alone</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>7 (29)</td><td colspan='1' rowspan='1' align='left'>8 (29)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>At home with other person</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>13 (54)</td><td colspan='1' rowspan='1' align='left'>20 (71)</td><td colspan='1' rowspan='1' align='left'>0.077<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>In institution or nursing home</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>4 (17)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='4' rowspan='1' align='left'>Education</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Less than basic</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>7 (29)</td><td colspan='1' rowspan='1' align='left'>8 (29)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Basic</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>8 (67)</td><td colspan='1' rowspan='1' align='left'>20 (71)</td><td colspan='1' rowspan='1' align='left'>0.870<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>More than basic</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='4' rowspan='1' align='left'>Ability to walk</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Independently</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>15 (65)</td><td colspan='1' rowspan='1' align='left'>24 (86)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>With assistive device</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>6 (26)</td><td colspan='1' rowspan='1' align='left'>4 (14)</td><td colspan='1' rowspan='1' align='left'>0.119<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>With help of another person</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>2 (9)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'></td></tr><tr valign='top'><td colspan='4' rowspan='1' align='left'>Diagnosed diseases</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Depression</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>5 (21)</td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0.084<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Alcohol-related disease</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>1.000<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Hypertension</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>10 (42)</td><td colspan='1' rowspan='1' align='left'>10 (36)</td><td colspan='1' rowspan='1' align='left'>0.660<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Hypercholesterolemia</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>3 (11)</td><td colspan='1' rowspan='1' align='left'>0.240<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Diabetes mellitus (type I or II)</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>5 (21)</td><td colspan='1' rowspan='1' align='left'>2 (7)</td><td colspan='1' rowspan='1' align='left'>0.227<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>TIA</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>4 (17)</td><td colspan='1' rowspan='1' align='left'>2 (7)</td><td colspan='1' rowspan='1' align='left'>0.397<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Cerebral infarct</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>0.462<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Cerebral hemorrhage</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>0.462<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Cerebral trauma</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>1.000<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Malignant tumor or cancer</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>0.462<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>HIV, lues or borreliosis</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>1.000<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Dementia (all types)</p></list-item></list></td><td colspan='1' rowspan='1' align='left'>1 (4)</td><td colspan='1' rowspan='1' align='left'>0 (0)</td><td colspan='1' rowspan='1' align='left'>0.462<xref rid='T4F2' ref-type='table-fn'><sup>**</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>Values denote means ± SD or numbers with percentages in parentheses.</p></fn><fn id='T4F1'><label>*</label><p>Mann-Whitney U test.</p></fn><fn id='T4F2'><label>**</label><p>χ<sup>2</sup> test or Fisher's exact test.</p></fn><fn><p>TIA = Transient ischemic attack.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation='portrait' id='T5' position='float'><label>Table 5</label><caption><p>Significant associations between the use of psychotropics or other drugs with CNS effects and change in cognitive functioning (MMSE) during a 7.6-year follow-up, by gender and age</p></caption><table rules='groups' frame='hsides'><thead><tr valign='bottom'><th colspan='1' rowspan='1' align='left'>Medication</th><th colspan='1' rowspan='1' align='left'>Age</th><th colspan='5' rowspan='1' align='left'>Baseline MMSE</th><th colspan='2' rowspan='1' align='left'>MMSE at follow-up</th><th colspan='4' rowspan='1' align='left'>Change in MMSE</th></tr><tr><th colspan='13' rowspan='1'><hr></hr></th></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'></td><td colspan='1' rowspan='1' align='left'></td><th colspan='2' rowspan='1' align='left'>users</th><th colspan='2' rowspan='1' align='left'>controls</th><th colspan='1' rowspan='1' align='left'>p</th><th colspan='1' rowspan='1' align='left'>users</th><th colspan='1' rowspan='1' align='left'>controls</th><th colspan='1' rowspan='1' align='left'>users</th><th colspan='1' rowspan='1' align='left'>controls</th><th colspan='1' rowspan='1' align='left'>p for diff.</th><th colspan='1' rowspan='1' align='left'>adjusted p</th></tr><tr valign='top'><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>n</th><th colspan='1' rowspan='1' align='left'>mean ± SD</th><th colspan='1' rowspan='1' align='left'>n</th><th colspan='1' rowspan='1' align='left'>mean ± SD</th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'>mean ± SD<sup>2</sup></th><th colspan='1' rowspan='1' align='left'>mean ± SD<sup>2</sup></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th><th colspan='1' rowspan='1' align='left'></th></tr></thead><tbody><tr valign='top'><td colspan='1' rowspan='1' align='left'>BZD<sup>1</sup></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>8</td><td colspan='1' rowspan='1' align='left'>20.9 ± 2.8</td><td colspan='1' rowspan='1' align='left'>11</td><td colspan='1' rowspan='1' align='left'>21.1 ± 3.3</td><td colspan='1' rowspan='1' align='left'>0.729</td><td colspan='1' rowspan='1' align='left'>12.3 ± 7.6</td><td colspan='1' rowspan='1' align='left'>17.8 ± 5.6</td><td colspan='1' rowspan='1' align='left'>−8.6 ± 7.0</td><td colspan='1' rowspan='1' align='left'>−3.3 ± 5.6</td><td colspan='1' rowspan='1' align='left'>0.116</td><td colspan='1' rowspan='1' align='left'>0.015</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>BZD<sup>2</sup></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>8</td><td colspan='1' rowspan='1' align='left'>20.9 ± 2.8</td><td colspan='1' rowspan='1' align='left'>22</td><td colspan='1' rowspan='1' align='left'>17.9 ± 7.5</td><td colspan='1' rowspan='1' align='left'>0.532</td><td colspan='1' rowspan='1' align='left'>12.3 ± 7.6</td><td colspan='1' rowspan='1' align='left'>15.6 ± 8.4</td><td colspan='1' rowspan='1' align='left'>−8.6 ± 7.0</td><td colspan='1' rowspan='1' align='left'>−2.3 ± 5.9</td><td colspan='1' rowspan='1' align='left'>0.027</td><td colspan='1' rowspan='1' align='left'>0.002</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'>Any psychotropic drug<sup>2</sup> (AP, BZD, AD)</td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>12</td><td colspan='1' rowspan='1' align='left'>16.9 ± 8.0</td><td colspan='1' rowspan='1' align='left'>18</td><td colspan='1' rowspan='1' align='left'>19.9 ± 5.5</td><td colspan='1' rowspan='1' align='left'>0.318</td><td colspan='1' rowspan='1' align='left'>11.0 ± 8.7</td><td colspan='1' rowspan='1' align='left'>17.2 ± 7.0</td><td colspan='1' rowspan='1' align='left'>−5.9 ± 7.0</td><td colspan='1' rowspan='1' align='left'>−2.7 ± 6.4</td><td colspan='1' rowspan='1' align='left'>0.309</td><td colspan='1' rowspan='1' align='left'>0.037</td></tr><tr valign='top'><td colspan='13' rowspan='1' align='left'>BZD <italic>and</italic></td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AP<sup>1</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>65+</td><td colspan='1' rowspan='1' align='left'>1</td><td colspan='1' rowspan='1' align='left'>23</td><td colspan='1' rowspan='1' align='left'>27</td><td colspan='1' rowspan='1' align='left'>21.5 ± 2.9</td><td colspan='1' rowspan='1' align='left'>0.415</td><td colspan='1' rowspan='1' align='left'>7</td><td colspan='1' rowspan='1' align='left'>20.1 ± 7.2</td><td colspan='1' rowspan='1' align='left'>−16</td><td colspan='1' rowspan='1' align='left'>−1.4 ± 7.8</td><td colspan='1' rowspan='1' align='left'>0.137</td><td colspan='1' rowspan='1' align='left'>0.038</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>AD<sup>1</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>3</td><td colspan='1' rowspan='1' align='left'>18.7 ± 3.8</td><td colspan='1' rowspan='1' align='left'>11</td><td colspan='1' rowspan='1' align='left'>21.1 ± 3.3</td><td colspan='1' rowspan='1' align='left'>0.371</td><td colspan='1' rowspan='1' align='left'>8.0 ± 1.7</td><td colspan='1' rowspan='1' align='left'>17.8 ± 5.6</td><td colspan='1' rowspan='1' align='left'>−10.7 ± 4.7</td><td colspan='1' rowspan='1' align='left'>−3.2 ± 5.6</td><td colspan='1' rowspan='1' align='left'>0.085</td><td colspan='1' rowspan='1' align='left'>0.021</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any drug with CNS effects<sup>1</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>65+</td><td colspan='1' rowspan='1' align='left'>5</td><td colspan='1' rowspan='1' align='left'>20.0 ± 3.3</td><td colspan='1' rowspan='1' align='left'>27</td><td colspan='1' rowspan='1' align='left'>21.5 ± 2.9</td><td colspan='1' rowspan='1' align='left'>0.329</td><td colspan='1' rowspan='1' align='left'>10.4 ± 10.5</td><td colspan='1' rowspan='1' align='left'>20.1 ± 7.2</td><td colspan='1' rowspan='1' align='left'>−9.6 ± 9.9</td><td colspan='1' rowspan='1' align='left'>−1.4 ± 7.8</td><td colspan='1' rowspan='1' align='left'>0.101</td><td colspan='1' rowspan='1' align='left'>0.038</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>ACh<sup>1</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>2</td><td colspan='1' rowspan='1' align='left'>18.6 ± 3.5</td><td colspan='1' rowspan='1' align='left'>11</td><td colspan='1' rowspan='1' align='left'>21.1 ± 3.3</td><td colspan='1' rowspan='1' align='left'>0.184</td><td colspan='1' rowspan='1' align='left'>3.5 ± 4.9</td><td colspan='1' rowspan='1' align='left'>17.8 ± 5.6</td><td colspan='1' rowspan='1' align='left'>−15.0 ± 8.5</td><td colspan='1' rowspan='1' align='left'>−3.3 ± 5.6</td><td colspan='1' rowspan='1' align='left'>0.059</td><td colspan='1' rowspan='1' align='left'>0.042</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any drug with CNS effects<sup>1</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>19.3 ± 3.3</td><td colspan='1' rowspan='1' align='left'>11</td><td colspan='1' rowspan='1' align='left'>21.1 ± 3.3</td><td colspan='1' rowspan='1' align='left'>0.279</td><td colspan='1' rowspan='1' align='left'>6.0 ± 4.4</td><td colspan='1' rowspan='1' align='left'>17.8 ± 5.6</td><td colspan='1' rowspan='1' align='left'>−13.3 ± 6.5</td><td colspan='1' rowspan='1' align='left'>−3.3 ± 5.6</td><td colspan='1' rowspan='1' align='left'>0.031</td><td colspan='1' rowspan='1' align='left'>0.003</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any drug with CNS effects<sup>2</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>65+</td><td colspan='1' rowspan='1' align='left'>5</td><td colspan='1' rowspan='1' align='left'>20.0 ± 3.3</td><td colspan='1' rowspan='1' align='left'>47</td><td colspan='1' rowspan='1' align='left'>20.0 ± 5.7</td><td colspan='1' rowspan='1' align='left'>0.603</td><td colspan='1' rowspan='1' align='left'>10.4 ± 10.5</td><td colspan='1' rowspan='1' align='left'>18.7 ± 8.3</td><td colspan='1' rowspan='1' align='left'>−9.6 ± 9.9</td><td colspan='1' rowspan='1' align='left'>−1.3 ± 7.2</td><td colspan='1' rowspan='1' align='left'>0.064</td><td colspan='1' rowspan='1' align='left'>0.045</td></tr><tr valign='top'><td colspan='1' rowspan='1' align='left'><list list-type='simple'><list-item><p>Any drug with CNS effects<sup>2</sup></p></list-item></list></td><td colspan='1' rowspan='1' align='left'>75+</td><td colspan='1' rowspan='1' align='left'>4</td><td colspan='1' rowspan='1' align='left'>19.3 ± 3.3</td><td colspan='1' rowspan='1' align='left'>26</td><td colspan='1' rowspan='1' align='left'>18.6 ± 7.0</td><td colspan='1' rowspan='1' align='left'>0.573</td><td colspan='1' rowspan='1' align='left'>6.0 ± 4.4</td><td colspan='1' rowspan='1' align='left'>16.0 ± 7.8</td><td colspan='1' rowspan='1' align='left'>−13.3 ± 6.5</td><td colspan='1' rowspan='1' align='left'>−2.6 ± 5.6</td><td colspan='1' rowspan='1' align='left'>0.009</td><td colspan='1' rowspan='1' align='left'>0.001</td></tr></tbody></table><table-wrap-foot><fn><p>p = p value for difference in MMSE at baseline between users and controls; p for diff. = p value for difference of change in MMSE between users and controls; adjusted p = p value for difference of change in MMSE between users and controls adjusted for confounding variables (age).</p></fn><fn><p><sup>1</sup> Control group: no medication with effects on CNS.</p></fn><fn><p><sup>2</sup> Control group: non-users of corresponding medications.</p></fn></table-wrap-foot></table-wrap></floats-group></article></PAPER>